Achieving optimal lipid values in patients with dyslipidemia is associated with reduced risk of cardiovascular events

Journal of Clinical Lipidology

Volumn 2, Issue 5, 2008, Pages 343-353

  Charland, Scott L ^a,f   Cziraky, Mark J ^b,f   Quimbo, Ralph ^b,f   Karas, Richard H ^c,f   Insull Jr , William ^d,f   Davidson, Michael ^e,f   Stanek, Eric J ^f  

^a UNIVERSITY OF COLORADO   (United States)

^b HEALTHCORE INC   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f Thorofare   (United States)

Author keywords

Cardiovascular diseases; Cardiovascular events; Cholesterol; Clinical practice; Dyslipidemia; Lipids; Lipoproteins; Managed care; Population study

Indexed keywords

BILE ACID SEQUESTRANT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MANAGED CARE; MONOTHERAPY; PRIMARY PREVENTION; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK REDUCTION;

EID: 53249115184     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2008.06.009     Document Type: Article

References (31)

1. American Heart Association Disease and Stroke Statistics-2008 Update (2008), American Heart Association, Dallas, TX
2. NCEP Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
3. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 suppl 1 (2008) S12-S54
4. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
5. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
6. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summaryFourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14 suppl. 2 (2007) E1-E40
7. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
8. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
9. Brown B.G., Stukovsky K.H., and Zhao X.Q. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol 17 (2006) 631-636
10. Superko H.R., and King III S. Lipid management to reduce cardiovascular risk: a new strategy is required. Circulation 117 (2008) 560-568
11. Taylor A.J., Sullenberger L.E., Lee H.J., et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517
12. Taylor A.J., Lee H.J., and Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 22 (2006) 2243-2250
13. Alsheikh-Ali A.A., Lin J.L., Abourjaily P., et al. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol 98 (2006) 1231-1233
14. Mosca L., Merz N.B., Blumenthal R.S., et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 111 (2005) 488-493
15. Sarawate C.A., Cziraky M.J., Stanek E.J., et al. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?. Clin Ther 29 (2007) 196-209
16. Stacy T.A., and Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J Manag Care Pharm 12 (2006) 745-751
17. Stanek E.J., Sarawate C., Willey V.J., et al. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr Med Res Opin 23 (2007) 553-563
18. Mosca L., Appel L.J., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 (2004) 672-693
19. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27 suppl 1 (2004) S68-S71
20. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
21. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 86 suppl. (2000) 19L-22L
22. Whitney E.J., Krasuski R.A., Personius B.E., et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142 (2005) 95-104
23. Koro C.E., Bowlin S.J., Stump T.E., et al. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J 151 (2006) 755
24. Arca M., Montali A., Valiante S., et al. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. Am J Cardiol 100 (2007) 1511-1516
25. Brown B. Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy. Eur Heart J Suppl 7 (2005) F34-F40
26. Gotto Jr. A.M. Establishing the benefit of statins in low-to-moderate-risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Atheroscler Suppl 8 (2007) 3-8
27. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285 (2001) 1585-1591
28. Sharrett A.R., Ballantyne C.M., Coady S.A., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104 (2001) 1108-1113
29. Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes. http://wwwaimhigh-heart.com/background.shtml Accessed November 11, 2007
30. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. http://clinicaltrialsgov/ct2/show/NCT00461630 Accessed February 14, 2008
31. Devine P.J., Turco M.A., and Taylor A.J. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS). Cardiovasc Drugs Ther 21 (2007) 221-225